Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group
Language English Country United States Media print-electronic
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- Keywords
- Multiple myeloma, cytogenetic abnormalities, prognosis, thalidomide,
- MeSH
- Survival Analysis MeSH
- Chromosome Deletion * MeSH
- Chromosome Duplication * MeSH
- In Situ Hybridization, Fluorescence MeSH
- Incidence MeSH
- Humans MeSH
- Chromosomes, Human, Pair 1 MeSH
- Chromosomes, Human, Pair 14 MeSH
- Chromosomes, Human, Pair 17 MeSH
- Chromosomes, Human, Pair 4 MeSH
- Multiple Myeloma epidemiology genetics mortality MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Translocation, Genetic * MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Poland epidemiology MeSH
The study aimed to assess prognostic significance of del(13q14), del(17p13), t(4;14)(p16;q32), and amp(1q21) in newly diagnosed myeloma patients treated mostly with thalidomide-based therapies. All genetic abnormalities except del(13q14) were independent prognostic factors associated with shortened progression-free survival (PFS) and overall survival (OS). Patients with no abnormalities, one abnormality, and ≥2 abnormalities had a median PFS of 41.8, 17.0, and 10.0 months, respectively; a median OS was not reached, 48.0 and 23.3 months, respectively. According to the presence of amp(1q21), t(4;14)(p16;q32), and del(17p13) and the International Staging System (ISS), we stratified patients into low-risk, intermediate-risk and high-risk groups. A median PFS was 52.9, 25.6, and 10.0 months, respectively; a median OS was not reached, 64.0 and 25.0 months, respectively. In conclusion, our study confirmed the prognostic value of cytogenetic changes and showed that prognostic models based on ISS and cytogenetic studies should include not only del(17p13) and t(4;14)(p16;q32), but also amp(1q21).
b Department of Experimental Hematooncology Medical University of Lublin Lublin Poland
c University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Ergonomics Faculty of Management Lublin University of Technology Lublin Poland
Department of Hematology St John's Cancer Center Lublin Poland
h Department of Hematology Jagiellonian University Medical College Cracow Poland
i Department of Biochemical Diagnostics Medical University of Lublin Lublin Poland
References provided by Crossref.org
